Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Hims and Hers Health Inc (HIMS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Hims and Hers Health Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $43.51 (market cap $746.48M), while Hims and Hers Health Inc trades at $30.92 (market cap $6.55B). The key difference: Hims and Hers Health Inc is far larger — about 8.8× Rex Fang & Innovation Equity Premium Income ETF's market cap, and Rex Fang & Innovation Equity Premium Income ETF is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Rex Fang & Innovation Equity Premium Income ETF for 56 Days and Hims and Hers Health Inc for 21 Days on average.
| FEPI | HIMS | |
|---|---|---|
Market Cap | $746.48M | $6.55B |
Volume | 334,337 | 14,842,814 |
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $62.76 |
52-Week Low | $37.98 | $14.52 |
Typical Hold Time | 56 Days | 21 Days |
Enterprise Value | — | $7.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $43.51, down 0.18% on the day, with a bullish technical signal from moving averages but neutral oscillators. The ETF employs a covered call strategy on AI and tech stocks, generating high weekly dividends but facing capped upside. Recent news highlights its 25% yield but notes underperformance versus peers in total return.
The outlook is mixed: high income appeals, but concentration in volatile tech and covered call limitations pose risks. Investors seeking yield may find value, yet must weigh potential underperformance if tech momentum slows. Risks include sector volatility and strategy constraints in rising markets.
Hims & Hers Health trades at $30.92, up 4.67% on the day, amid a bearish technical signal and significant legal headwinds from multiple securities class action lawsuits. The stock shows mixed fundamentals with strong revenue growth to $2.35 billion in 2025 but a sharp reversal to a net loss of -$142 million in 2026, reflecting profitability challenges. Valuation ratios appear elevated with a P/E of 57.14 and EV/EBITDA of 205.86, while analyst consensus remains cautiously optimistic with a $32.17 price target.
The outlook is clouded by legal risks and recent earnings misses, though the company's gross margin of 68.43% indicates underlying business strength. Investment opportunity hinges on resolving regulatory scrutiny and returning to profitability, but near-term volatility is likely. Key risks include the FTC lawsuit outcome and sustained negative cash flow, demanding careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →
